cyrilzakka/clinical-trials huggingface dataset:
Elastic Band Training Effects on Knee Strength and Performance in Female Football Players

The goal of this clinical trial is to assess the effects of an 8-week strength training program with elastic bands on several physical components in female football players at the U15, U19, and Senior levels. The main question it aims to answer is:

Will a specific elastic band resistance training help improve some components of physical performance in female football players?

Participants will perform a bi-weekly elastic band resistance training program lasting 20 minutes per session over 8 weeks. This program will be incorporated into their in-season regimen, with assessments conducted in the week prior (week 0) and after the intervention (week 9).

This study will involve U15´, U19´ and adult female football (soccer) players doing a specific elastic band training plan over a period of 8 weeks. This plan will be done twice a week and will consist of 6 exercises, divided into two training sessions, each lasting approximately 20 minutes.

The week before the study begins (week 0), a demonstration will be given of the assessments and training plan that will be carried out during the following weeks, so that the participants have a better idea of what will happen. In addition, their height and weight will also have to be measured, followed by the first assessments. They will also fill in a questionnaire about their training habits and injury history.

They will then be randomized into two possible groups: the experimental group (EG) and the control group (CG). If the participant stays in the EG, she will have to do the above protocol and if she stays in the CG, she will only have to do the assessments, which will be done in the familiarization week (week 0) and the ninth week (week 9).

Eligibility Criteria:
Inclusion Criteria:

* belong to the U-15, U-19 or Senior level of a women's football (soccer) club;
* be apart of a football championship (district or national)
RHYTHMIC STIMULUS EFFECTS ON NEURONAL OSCILLATORY ACTIVITY AND SPEACHES CAPABILITIES IN DEAF CHILDREN

The deaf children showed deficits in speech processing and temporality. They badly apprehend temporal concepts and perceptions of deficit so the acoustic phenomena marking the time course linguistically. Their prediction capabilities and anticipation multisensory events are thereby affected, thus impacting their ability to adapt to multiple and complex interaction possibilities that arise during a conversation.The project aim it is to measure the impact of a musical rhythmic stimulation of neuronal activity and the temporal prediction capabilities of older deaf children 5 to 8 years and its impact on their language skills in a conversational task. A matched control group of age will be examined for each of the proposed tasks.

We first measure the capacity to anticipate a situation of language interaction. For this purpose, we will use an alternate naming paradigm with a virtual partner, already developed and tested in children with normal hearing. This paradigm approaches the conversational situation while allowing control of the time parameter of speech (speed of trade) and by controlling the bias (temporal) inherent linguistic programming difficulties of children in a spontaneous conversation situations .

Then we will couple behavioral measurements with measurements of eye movements and the electroencephalogram (EEG) in deaf children. For this, we use a dialog observation task already developed for normal hearing children. This task will allow us firstly to analyze the anticipation level of speaking turns by analyzing eye movements (which "precedes" the speaker). Secondly, it will allow us to study the effects of manipulation of the acoustic parameters of auditory evoked potentials (AEP) and the oscillatory activity of the motor system (EEG, mu rhythm and beta). The audiomoteur coupling would seem to be the key point of anticipatory processes and convergence in conversational interaction will also be studied using cortico-cortical coherence techniques to assess the dynamics of connectivity between remote networks (system here auditory and motor system).


Eligibility Criteria:
Inclusion Criteria:

* prélingual paired deaf or implanted cochlear children.

Exclusion Criteria:

* Childreen with other major disabilities and associated disorders.
* Clidren with failure to understand instructions either directly oral or sign language.
Kinematic Versus Mechanical Alignment in Total Knee Replacement

This prospective controlled double-blind randomized study compares kinematic and mechanical alignment in TKA (Total knee arthroplasty). A total of 120 patients will be included and the surgery will be performed using CT based 3D printed PSI(Patient Specific Instruments) Cutting guides.

Total knee arthroplasty (TKA) is known, to significantly improve function and satisfaction in arthritic knee patients; nevertheless, a substantial percentage of these patients are not fully satisfied. Thus, several authors reported significantly improved outcomes after slightly under correcting varus knees after TKA. The concept of kinematic alignment (KA) even more addresses the patient´s individual anatomy with three-dimensional restoration of individual axes, joint lines and joint envelope of laxity. The aim of this prospective randomized study was to demonstrate equivalence between mechanical and kinematic alignment in restoring knee function in terms of subjective and objective outcomes.

In this prospective randomized controlled double-blind study 120 patients with osteoarthritic knees will be treated with a Medial Pivot TKA (Medacta Sphere GMK). The patients are divided into two groups. Group A receive the TKA using mechanical alignment principles, group B receive the kinematic alignment. The surgical technique was equal in both groups. CT-based 3D printed PSI cutting blocks were used for the saw cuts. Pre and postoperative standard x-rays were performed. To determine the subjective and objective outcomes the OKS(Oxford Knee Score), the KSS(Knee Society Sore), the FJS-12(Forgotten Joint Score) and the WOMAC Score were collected.

Eligibility Criteria:
Inclusion Criteria:

* Symptomatic osteoarthritis of the knee
* Primary TKA
* UCLA Score (University of California, Los Angeles Score)\>/= 4
* mMPTA: 85°- 90°
* Sum of mMPTA(mechanical medial proximal tibial angle) and mLDFA(mechanical lateral distal femoral angle) between 3°varus and 2°valgus from neutral

Exclusion Criteria:

* Minor Patient
* Pregnant or breast feeding woman
* Difference in the radius of medial and lateral condyles \>2mm
* Previous osteotomy around the knee
* BMI \>40
* Ligament instability likely to require higher level of constraint
* Previous infection or inflammatory disease
* Any Patient who cannot or will not provide informed consent for participation in the study
Measurement of Total Retinal Blood Flow During Flicker Stimulation in Healthy Subjects

Neurovascular coupling or functional hyperemia is defined as an essential physiologic mechanism in the brain, which is necessary for the local adaption of blood flow to altered metabolic demands of the tissue. It has been shown that also in the eye, blood flow is considerably coupled to retinal neural activity. The current concept of functional hyperemia is that visual stimulation, as flicker light, effectuates increasing neural activity in the retina, which elevates the metabolic needs of the retinal tissue for oxygen and glucose and consequently induces dilatation and augmented blood flow in the retinal vasculature. In several studies, stimulation with flicker light has been shown to induce an increase of blood flow in major retinal arteries and veins as well as an increase of optic nerve head blood flow. Up until now, flicker induced changes in blood flow were measured solely in the major retinal arteries and veins with systems such as the commercially available dynamic vessel analyzer (DVA) by Imedos and with laser Doppler velocimetry (LDV).

In the present study, the investigators propose to measure the response of total retinal blood flow to diffuse luminance flicker stimulation with bi-directional Fourier Domain Doppler Optical Coherence Tomography (FDOCT) as well as with Laser Speckle Flowgraphy (LSFG) in healthy subjects by assessing vessel diameter, blood velocity and blood flow of all retinal vessels. For comparative reasons, the investigators will furthermore assess the blood flow of major retinal arteries and veins with the dynamic vessel analyzer (DVA) and laser Doppler velocimetry (LDV).


Eligibility Criteria:
Inclusion Criteria:

* Informed consent for participation
* Men and women aged between 18 and 45 years
* Non-smokers
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
* Systolic blood pressure \< 140 mmHg, diastolic blood pressure \< 90 mmHg
* Normal ophthalmic findings, ametropia less than 3 diopters

Exclusion Criteria:

* History or presence of ocular disease
* Ametropy ≥ 3 dpt
* Treatment with any drug in the 3 weeks preceding the first study day
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Participation in a clinical trial in the 3 weeks preceding the first study day
* Blood donation during the 3 weeks preceding the first study day
* History of family history of epilepsy
* Abuse of alcoholic beverages
* Pregnancy
Livertoxcicity in Acute Leukemia Patients During Chemotherapy Treatment

Detection of hepatotoxcicity in acute leukemia and study the outcome of acute leukemia patients that suffer from hepatic toxiciyt

Chemotherapy induction associated with hepatotoxicity during the induction has never been studied the study aimed to determine whether chemotherapy induction is associated with livertoxicity or not

Eligibility Criteria:
Inclusion Criteria:

* patients newly diagnosed with acute leukemia who are going to start chemotherapy treatment

Exclusion Criteria:

* patients previously diagnosed Acute leukemia and started treatment or in post treatment follow up
Protein and Satiety in Older Adults (PROSAT)

This study aims to assess the effect of protein on appetite, food intake and gastric emptying in older adults (≥ 65 years) that are more and less active.

To investigate the differences in food intake in older adults that are more or less active and assess any differential responses to protein intake.

To compare the effect of meals with high or low protein level but equal in energy and volume on appetite and gastric emptying in older adults that are more or less active (≥ 65 years).

Eligibility Criteria:
Inclusion Criteria:

* healthy
* aged ≥ 65 years

Exclusion Criteria:

* having diabetes or disability or any disease that are likely to influence physical activity or appetite.
* having an allergy to any of the test foods;
* disliking or cannot eat any of the test foods;
* being obese (BMI \> 30 kg/m2);
* taking medications known to influence appetite, food intake or body weight in the past three months;
* being on a weight loss diet;
* smoking more than 10 cigarettes a day;
* not meeting the cut-off point criteria based on the accelerometer data (108.25 ≤ min/per day of moderate and vigorous activity for women or 162 ≥ min/per day moderate and vigorous activity for women and 100.1 ≤ min/per day of moderate and vigorous activity for men or 133.25 ≥ min/per day moderate and vigorous activity for men).
Dietary Modification in Inflammatory Bowel Disease Patients

This research project aimed to develop a culturally appropriate Asian Inflammatory Bowel Disease Diet for the Malaysian population, based on the Crohn's disease exclusion diet (CDED). The study will be conducted in inflammatory bowel disease patients in University Malaya Medical Centre, which are ulcerative colitis and Crohn's disease patients. The objectives of this study are to assess the impact of diet in clinical outcome and gut microbiota changes in patients with inflammatory bowel disease (IBD). The study duration spans 24 weeks, during which comprehensive follow-ups will be conducted at 0, 6, 12, and 24 weeks, respectively. At each follow-up session, participants will be requested to provide stool and blood samples for meticulous assessment of clinical and biochemical responses.

Inflammatory bowel disease is a chronic gut inflammation due to immune system dysregulation. Although the exact causes remain unknown, patients' dietary habits were shown to affect the disease activity depending on the food exposure, either proinflammatory or anti-inflammatory food. This randomized-controlled trial (RCT) study aims to improve the modified CDED diet that is acceptable for the Malaysian population at Universiti Malaya Medical Centre. This study comprised of three parts: (Part 1: In-depth interview to measure the acceptance of the diet, Part 2: Implementation of the CDED diet, Part 3: Identification of change in gut microbiome post dietary intervention). The duration of the study is two years.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of Crohn's disease according to established clinical, endoscopic, and histological criteria.
* Mild to moderate diseases (150 to 220 points).
* Written informed consent obtained.

Exclusion Criteria:

* Presence of stoma.
* Surgery within 6 months prior to randomization.
* Patient on exclusive enteral nutrition (EEN).
Relation Between COVID-19 Pts and Hyponatremia in Adreno Ortical Insufficient Patients.

Hyponatremia in COVID-19 patients with adrenal insufficiency

Hyponatremia is the most prevalent hydroelectrolytic disorder in clinical practice, and is linked to higher rates of morbidity and mortality. 1, 2.Sodium balance disorder, particularly hyponatremia, is a common condition among hospitalized patients with COVID-19 . and it is associated with a higher risk of morbidity, mortality, and disability. Acute hyponatremia causes serious brain swelling that can lead to permanent disability or death. Chronic hyponatremia causes attention deficit, gait instability, and osteoporosis, Mechanisms of hyponatremia in coronavirus disease 2019 (COVID-19) patients. Osmotic syndrome of inappropriate antidiuretic hormone release (SIADH) as a major mechanism. Also hypovolemic hyponatremia that may have been common in COVID-19 patients since nausea, vomiting, diarrhea.we predict critical illness-related corticosteroid insufficiency (CIRCI) play a role in hyponatremia in COVID-19 , high percentage of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection in the study were treated with vasopressors (2). Angiotensin-converting enzyme 2 receptor and transmembrane serine protease 2 serine protease were colocalized in adrenocortical cells in the zona fasciculata and zona reticularis (2). plasma cortisol concentrations will be collected in critically ill patients with COVID-19 (2). The cortisol levels of critically ill patients with COVID-19 were low(2).We aimed to identify the previlence and mortality rate of hyponatremia in covid 19 patient with adrenal insufficiency . Our studies will present in Assiut hospital university on patients in isolation ward from October 2021 to October 2022.

Eligibility Criteria:
Inclusion Criteria:

* 1-Suspected COVID-19 patients come to isolation hospital in Assuit. 2-Hyponatremia. 3- Adrenal insufficiency

Exclusion Criteria:

* Non-cooperative patients
Increasing the Effectiveness of the Diabetes Prevention Program

The Diabetes Prevention Program (DPP) is highly effective in promoting weight loss in overweight and obese individuals (e.g., 7% average loss of body weight), and thereby reducing the risk of developing weight-related health consequences. One-on-one DPP sessions, however, are costly and the group-delivered DPP version, the Group Lifestyle Balance program (GLB), is less effective (4% average loss of body weight). The aim of this two-arm parallel randomized controlled trial is to increase the effectiveness of the GLB by integrating habit formation techniques, namely if-then plans and their mental practice, into the program. The study will provide evidence-based data on the effectiveness of an enhanced GLB intervention in promoting weight loss and in reducing weight-related risk factors for chronic health problems.

Please see brief summary.

Eligibility Criteria:
Inclusion Criteria:

* men and women
* ages of 18 and 75
* overweight or obese (BMI 28-45 kg/m2)
* sedentary (\< 200 min/week of moderate or vigorous exercise)
* waist circumference of \>= 88cm for women and \>= 102cm for men

Exclusion Criteria:

* diabetes (hemoglobin A1c \< 7.0%).
* taking the medication metformin (used for treating pre-diabetes or diabetes)
* having been pregnant in the past 6 months or planning on becoming pregnant in the next 2 years
* currently undergoing treatment for cancer
* using medication that affects body weight (e.g., loop diuretics)
* being unable to participate in regular moderate physical activity
* having severe uncontrolled hypertension (\> 190/100mm Hg)
* being unable to communicate in English or French
* being diagnosed with bulimia nervosa, currently active major depression, or other severe psychiatric disease (including dementia);
* suffering from a heart attack, stroke, or heart failure within the past 6 months
* experiencing excessive weight loss (more than 10 pounds or 4.54 kilograms) in the past 3 months
* currently participating in another weight loss program
* having had bariatric surgery in the past 2 years or plans on getting it in the near future
* planning on moving away from Montreal within the next year
* having another member of one's household enrolled in the program.
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia

The purpose of this study is to collect a blood sample from patients with Chronic Lymphocytic Leukemia (CLL) and from volunteers without CLL.

The blood sample will be used in the laboratory to perform focused studies on Chronic Lymphocytic Leukemia (CLL).

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
* Normal donors who have no history of active or prior hematologic malignancy.

Exclusion Criteria:

* Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL, other hematologic malignancy or other disease process within the past 2 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
* Normal donors who have a history of steroid use, immunosuppression therapy or autoimmune disease are excluded.
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

Comparison of the effect of Atomoxetine and psychoeducation with placebo and psychoeducation after 10 weeks of treatment


Eligibility Criteria:
Inclusion Criteria:

* Meet the criteria for ADHD of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) as well as severity criteria. Diagnosis is assessed by the investigator's clinical evaluation as well as administration of the K-SADS-PL structured interview.
* Meet a symptom severity threshold of 1.5 standard deviations above age and sex norms for their diagnostic subtype on the ADHDRS-IV-Parent: Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) This severity threshold must be met at Visit 1 and maintained at Visit 2.
* Be at least 7 years of age, but not yet have reached their 16th birthday prior to Visit 1, when informed consent is obtained.
* For female subjects of child-bearing potential only, test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control.

Exclusion Criteria:

* Weigh less than 20 kg at study entry
* Have a documented history of Bipolar Disorder or any history of psychosis or pervasive development disorder (autistic spectrum disorder).
* Are pregnant or breastfeeding.
* Are at serious suicidal risk as assessed by the investigator.
* Have been treated previously for ADHD with pyschostimulants such as Methylphenidate or Ritalin
Mobile and Remote Monitoring of Seating Pressure for Wheelchair Users With SCI

This study will examine two interventions to increase weight shifts, overall trunk movement, and self-efficacy related to pressure ulcer prevention in wheelchair users with a spinal cord injury (SCI).

Participants will use a mobile seat interface pressure mapping system that gives them live, real-time, visual feedback on the distribution of pressure between them and their seat cushion. This type of feedback works as a compensatory strategy for lack of sensation and allows the individual to visually observe pressure distribution they are not able to feel. Additionally, the participants will be provided with structured pressure ulcer prevention education, grounded in the principles of social cognitive theory, regarding pressure ulcer risk and use of weight shifts.

The pressure mapping system, which will be used during training, provides virtual modeling of the desired outcome (reduced pressure) and is an important part of the education module.

The findings of this study will inform clinicians and investigators of whether use of mobile seat interface pressure mapping as a compensatory-based intervention has a positive impact on trunk movement and self-efficacy for completing weight shifts in wheelchair users who lack sensation. Another contribution of this work is an exploration of the relationship between self-efficacy and movement in wheelchair users.

Eligibility Criteria:
Inclusion Criteria:

* Individuals with a spinal cord injury (C4 and below, traumatic or non-traumatic, with onset greater than 12 months at enrollment)
* Individuals who use a wheelchair as their primary form of mobility
* Individuals who are willing to participate and able to make 2 visits to the Mayo Clinic in Rochester, MN

Exclusion Criteria:

* Documented active pressure ulcer of any stage at initiation of study
Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

This study is to assess the pharmacokinetics (PK) of a single dose of pravastatin with and without concomitant GDC-0810 administration in healthy female subjects of non-childbearing potential. During Period 1 (Day -1 to Day 4) PK parameters of pravastatin will be determined in the absence of GDC-0810. During Period 2 (Days 5-28) PK parameters of pravastatin will be determined in the presence of GDC-0810.


Eligibility Criteria:
Inclusion Criteria:

* Female subjects between 18 and 65 years of age, inclusive.
* Female subjects of non-childbearing potential including non-pregnant, non-lactating, and either postmenopausal or surgically sterile for at least 45 days post procedure.
* Within BMI range 18.5 to \</= 29.9 kg/m\^2, inclusive.
* In good health, as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.
* Receive an explanation of the mandatory pharmacogenomic (PgX) component of the study.

Exclusion Criteria:

* Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder.
* Previous history of adverse reaction to statins.
* Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) in Period 1.
* Use of systemic hormone replacement therapy within 1 year prior to Check-in (Day -1).
* History of use of tamoxifen, aromatase inhibitor or any other endocrine agent for treatment of breast cancer.
* Female subject is pregnant lactating, or breast feeding.